Home » Stocks » STTK

Shattuck Labs, Inc. (STTK)

Stock Price: $49.64 USD -0.36 (-0.72%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 2.05B
Revenue (ttm) 10.76M
Net Income (ttm) -27.41M
Shares Out 39.84M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $49.64
Previous Close $50.00
Change ($) -0.36
Change (%) -0.72%
Day's Open 50.05
Day's Range 47.14 - 51.34
Day's Volume 75,255
52-Week Range 19.00 - 57.61

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

AUSTIN, TX and DURHAM, NC, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional f...

GlobeNewsWire - 2 weeks ago

AUSTIN, TX and DURHAM, NC, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional f...

GlobeNewsWire - 1 month ago

AUSTIN, TX and DURHAM, NC, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional f...

GlobeNewsWire - 2 months ago

AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional f...

GlobeNewsWire - 2 months ago

– Initiated Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), for the treatment of ovarian cancer –

GlobeNewsWire - 2 months ago

AUSTIN, TX and DURHAM, NC, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional f...

GlobeNewsWire - 2 months ago

AUSTIN, TX and DURHAM, NC, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional f...

Seeking Alpha - 2 months ago

After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular wa...

Other stocks mentioned: AYLA, FUBO, GAN, INTZ, KC, KRON, SPRB
GlobeNewsWire - 2 months ago

DURHAM, N.C. and AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-funct...

Business Wire - 3 months ago

DURHAM, N.C. & AUSTIN, Texas--(BUSINESS WIRE)--Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new cla...

Benzinga - 3 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: CCL, BAM, FUBO, HEI, KRON
Business Wire - 3 months ago

DURHAM, N.C. & AUSTIN, Texas--(BUSINESS WIRE)--Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new cla...

Seeking Alpha - 3 months ago

U.S. IPO Weekly Recap: Healthcare Dominates A 7 IPO Week

Other stocks mentioned: FUBO, INTZ, KRON, MAACU, MUDSU, NGACU, SPRB
Market Watch - 3 months ago

Shares of Shattuck Labs Inc. soared in their public debut, as they opened 30% above the initial public offering price. The stock's first trade was at $22.10 at 11:10 a.m.

Market Watch - 3 months ago

Shattuck Labs Inc. said its initial public offering, which was upsized by about 19%, priced above the expected range at $17 a share, as the Texas-based biotechnology company focused on cancer ...

Business Wire - 3 months ago

DURHAM, N.C. & AUSTIN, Texas--(BUSINESS WIRE)--Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new cla...

About STTK

Shattuck Labs, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.

Industry
Research and Development in Biotechnology
IPO Date
Oct 9, 2020
Stock Exchange
NASDAQ
Ticker Symbol
STTK
Full Company Profile

Financial Performance

In 2019, Shattuck Labs's revenue was $9.89 million, a decrease of -55.94% compared to the previous year's $22.44 million. Losses were -$23.98 million, 224.6% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Shattuck Labs stock is "Strong Buy." The 12-month stock price forecast is 54.50, which is an increase of 9.79% from the latest price.

Price Target
$54.50
(9.79% upside)
Analyst Consensus: Strong Buy